Effects of tadalafil treatment combined with physical activity in patients with low onset hypogonadism: results from a not-randomized single arm phase 2 study.
作者： Rosita A. Condorelli , Aldo E. Calogero , Maurizio Di Mauro , Laura M. Mongioì , Giorgio I. Russo
DOI: 10.1080/13685538.2016.1177717
关键词:
摘要: AbstractPurpose: To investigate a possible relation between penile Doppler ultrasound examination (PDUE) parameters and efficacy of chronic therapy with tadalafil (TAD) combined protocol aerobic physical activity (PA) in patients late onset hypogonadism (LOH). Methods: The study evaluated 30 consecutively enrolled LOH erectile dysfunction which present contraindication to hormonal replacement for concomitant prostate disease. These were subjected phosphodiesterase V selective inhibitors (TAD 5 mg daily) PA.Results: After three months, we observed significant improvements function [IIEF-5, median (IQR) = 13.0 (7.0–18.0) versus 6.0 (5.0–6.75); p < 0.01] the main metabolic [homeostatic model assessment index, (IQR) = 2.5 (1.62–3.37) 3.0 (2.0–3.75); p < 0.01; body mass (IQR) = 27.0 (24.0–28.75) 27.5 (24.0–29.5)] vascular [peak systolic velocity, ...
sci-hub.se 参考文章(43)
Wei Zhang, Peng Li, Zhi-Kang Cai, Jun-Hua Zheng, Ji-Can Dai, Yi-Xin Wang, Zhong Wang, Zheng Li, None, [Safety and efficacy of L-carnitine and tadalafil for late-onset hypogonadism with ED: a randomized controlled multicenter clinical trial]. National journal of andrology. ,vol. 20, pp. 133- 137 ,(2014)
R. Pofi, D. Gianfrilli, R. Badagliacca, C. Di Dato, M. A. Venneri, E. Giannetta, Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work? Journal of Endocrinological Investigation. ,vol. 39, pp. 131- 142 ,(2016) , 10.1007/S40618-015-0339-Y
Liang Chen, Sergej E.L. Staubli, Marc P. Schneider, Alfons G. Kessels, Sandra Ivic, Lucas M. Bachmann, Thomas M. Kessler, Phosphodiesterase 5 Inhibitors for the Treatment of Erectile Dysfunction: A Trade-off Network Meta-analysis European Urology. ,vol. 68, pp. 674- 680 ,(2015) , 10.1016/J.EURURO.2015.03.031
Suresh C. Sikka, Wayne J.G. Hellstrom, Gerald Brock, Antonio Martin Morales, Standardization of Vascular Assessment of Erectile Dysfunction The Journal of Sexual Medicine. ,vol. 10, pp. 120- 129 ,(2013) , 10.1111/J.1743-6109.2012.02825.X
Shin-ichi Hisasue, Contemporary perspective and management of testosterone deficiency: Modifiable factors and variable management. International Journal of Urology. ,vol. 22, pp. 1084- 1095 ,(2015) , 10.1111/IJU.12880
Michał Rabijewski, Lucyna Papierska, Roman Kuczerowski, Paweł Piątkiewicz, Hormonal determinants of erectile dysfunction and lower urinary tract symptoms in middle-aged and elderly men with prediabetes The Aging Male. ,vol. 18, pp. 256- 264 ,(2015) , 10.3109/13685538.2015.1083972
Giulia Rastrelli, Giovanni Corona, Francesco Lotti, Antonio Aversa, Marco Bartolini, Mario Mancini, Edoardo Mannucci, Mario Maggi, None, Flaccid Penile Acceleration as a Marker of Cardiovascular Risk in Men without Classical Risk Factors The Journal of Sexual Medicine. ,vol. 11, pp. 173- 186 ,(2014) , 10.1111/JSM.12342
Dany‐Jan Yassin, Gheorghe Doros, Peter G. Hammerer, Aksam A. Yassin, Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. The Journal of Sexual Medicine. ,vol. 11, pp. 1567- 1576 ,(2014) , 10.1111/JSM.12523
Michael Zitzmann, The Role of the CAG Repeat Androgen Receptor Polymorphism in Andrology Frontiers of Hormone Research. ,vol. 37, pp. 52- 61 ,(2009) , 10.1159/000175843
JinQiu Yuan, RenJie Zhang, ZuYao Yang, Jack Lee, YaLi Liu, JinHui Tian, XiWen Qin, ZhengJia Ren, Hong Ding, Qing Chen, Chen Mao, JinLing Tang, Comparative Effectiveness and Safety of Oral Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction: A Systematic Review and Network Meta-analysis European Urology. ,vol. 63, pp. 902- 912 ,(2013) , 10.1016/J.EURURO.2013.01.012